Biogen And Millennium May Be Ensnared In Tentacles Of Genentech’s Expired Cabilly Patent
Executive Summary
Genentech claims Biogen and Millennium owe royalties on sales of Tysabri and Entyvio that were stockpiled when the Cabilly patent expired. Hospira faced similar litigation over its erythropoietin biosimilar and had to pay Amgen $70m in damages.
You may also be interested in...
Biosimilar Safe Harbors Need Record Of Non-Commercial Use, Epogen Ruling Suggests
Federal Circuit affirms jury's $70m award to Amgen and finding that some Hospira biosimilar batches were not protected by the safe harbor. Decision conveys how biosimilar makers can obtain this protection from infringement suits.
Brand vs. Brand Patent Battles Heat Up, Focus On Big Drug Classes
Patent brawl between Merck and Gilead involving Sovaldi and Harvoni was one of the marquee litigation events of 2016; a compilation of disputes between brand-name companies over the past six years shows how consequential they can be.
Patent Reviews Gave Innovators Headaches In 2015; Will Relief Come This Year?
Inter partes review process picked up steam as generic manufacturers, biosimilar sponsors, and hedge fund manager Kyle Bass filed slew of petitions challenging validity of drug patents.